直肠癌患者组蛋白甲基转移酶hSETD1A表达水平的临床预后价值  

Prognostic significance of histone methyltransferase hSETD1A expression in rectal cancer

作　　者：王淋[1] 贾静[1] 叶星明[1] 林露[1] 陈燕坪[2] 陈颖[1] WANG Lin;JIA Jing;YE Xingming;LIN Lu;CHEN Yanping;CHEN Ying(Central Laboratory,Fujian Cancer Hospital&Fujian Medical University Cancer Hospital,Fuzhou 350014,Fujian Province,China;Department of Pathology,Fujian Cancer Hospital&Fujian Medical University Cancer Hospital,Fuzhou 350014,Fujian Province,China)

机构地区：[1]福建省肿瘤医院,福建医科大学附属肿瘤医院中心实验室,福建福州350014 [2]福建省肿瘤医院,福建医科大学附属肿瘤医院病理科,福建福州350014

出　　处：《中国癌症杂志》2020年第5期369-374,共6页China Oncology

基　　金：福建省科技计划引导性项目(2017Y0020);福建省自然科学基金(2019J01192)。

摘　　要：背景与目的:组蛋白修饰是非常重要的表观遗传修饰形式,组蛋白甲基化修饰酶基因的异常表达与多种疾病及癌症的发生、发展有关。探讨直肠癌患者肿瘤组织的组蛋白甲基转移酶hSETD1A表达水平与临床预后的相关性。方法:选取2012年1月-2014年6月福建省肿瘤医院有详细临床资料和预后随访信息的直肠癌患者肿瘤组织切除标本141例及癌旁组织标本50例。采用免疫组织化学法检测h SETD1A的表达情况,分析其与直肠癌临床病理学特征(年龄、性别、肿瘤大小、T分期、淋巴结转移、神经累及等参数)及预后的关系。结果:肿瘤组织中h SETD1A的阳性表达率明显高于癌旁组织(75.2%vs26.0%,P<0.001)。此外,其阳性率的高低还与患者性别及肿瘤分化程度的不同相关(P=0.009)。而与年龄、肿瘤大小、T分期、淋巴结转移、TNM分期、神经累及、脉管癌栓、血清癌胚抗原(carcinoembryonic antigen,CEA)及CA19-9水平无关。生存分析结果显示,h SETD1A阳性组的5年生存率明显低于h SETD1A阴性组(64.4%vs 76.5%,P=0.036)。多因素COX回归分析显示,h SETD1A表达和T分期、淋巴结转移状况(N分期)是直肠癌的独立预后因素。结论:肿瘤组织hSETD1A的表达水平与直肠癌患者的预后密切相关。Background and purpose: Histone modification is an important form of epigenetic modification. Aberrant epigenetic modifications can result in a variety of diseases and cancers. Aim of the present study was to investigate the prognostic value of the histone methyltransferase hSETD1 A expression in rectal cancer patients. Methods: A total of 141 rectal cancer patients who underwent surgical operation between Jan. 2012 and Dec. 2014 at Fujian Cancer Hospital were enrolled in the study. The expression of hSETD1 A was detected by immunohistochemistry in all cancer tissues and 50 adjacent normal mucosa tissue samples. The KaplanMeier curves and COX regression models were applied for the evaluation of hSETD1 A in predicting the long-term outcomes of the patients. Results: Expression of hSETD1 A was significant higher in cancer tissues compared with adjacent mucosa tissues(75.2% vs 26.0%, P<0.001). In addition, the positive rate of hSETD1 A expression was related to gender and tumor differentiation grade(both P=0.009). However, it was not related to the variation of age, tumor size, lymph node metastasis, TNM stage, presence of perineural invasion or vascular tumor thrombus and the serum levels of carcinoembryonic antigen(CEA) or CA19-9. Survival analysis revealed patients with positive hSETD1 A expression had worse 5-year survival rate than those with negative expression of hSETD1 A(64.4% vs 76.5%, P=0.036). Furthermore, COX analysis identified hSETD1 A, T and N stages were independent prognostic factors in rectal cancer patients. Conclusion: hSETD1 A is highly expressed in rectal cancer, which is proposed as an independent prognostic factor.

关 键 词：直肠癌 组蛋白甲基化转移酶 hSETD1A 免疫组织化学 预后 

分 类 号：R735.37[医药卫生—肿瘤]